Novel Compounds Acting Through Receptors and Enzyme Mediators
This article will introduce novel steroids that have an optimal profile for the prevention of postmenopausal osteoporosis. These agents have a duality of function: they can activate the estrogen receptor (ER) but they also regulate the amount of ligand available for the ER via enzyme inhibition in a tissue-specific manner. These agents have the same clinical profile as selective estrogen receptor modulators (SERMS) but a different mode of action. This article will develop these mechanistic concepts.
KeywordsEstrogen Receptor Invasive Lobular Carcinoma Selective Estrogen Receptor Modulator Hydroxysteroid Dehydrogenase Hormone Response Element
Unable to display preview. Download preview PDF.
- 2.Kuiper GGJM, Nilson S, Gustaffsson J-A. Characteristics and function of the novel estrogen receptor β. In: O’Malley BW, editor. Hormones and signaling. New York: Academic Press, 1998: 90–112.Google Scholar
- 3.Truss M, Beato, M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocrine Rev 1993; 14:459–79.Google Scholar
- 11.Jin Y, Penning, TM. Steroid 5α-reductases and 3a-hydroxysteroid dehydrogenases: Keyenzymes in androgen metabolism. In: Seckl, JR, Walker, BR editors. Disorders of steroid metabolism. Holly, JMP, series editor. Best Practice & Research: Clinical Endocrinology and Metabolism. London: Bailliare Tindall 2000; 15:79–94.Google Scholar
- 16.Penning TM, Burczynski ME, Jez JM, et al. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AK1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351:67–77.PubMedCrossRefGoogle Scholar
- 17.Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko, RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic celland tissue-specific expression. Biochem J 1966; 314:839–45.Google Scholar
- 21.Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anti-cancer Res 1997; 17:135–40.Google Scholar
- 22.Chetrite G, Kloosterboer HJ, Phillipe J-C, Pasqualini, JR. Effects of Org OD14 (Livial) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anti-cancer Res 1999; 19:261–68.Google Scholar
- 23.Kloosterboer HJ, de Gooyer ME. Tibolone inhibits sulfatase activity in breast but not in the bone. Proceedings 9th International Menopause Symposium 1999 Oct 17–21; Yokohama, Japan P349.Google Scholar